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We have previously demonstrated that [3H]dynorphin A selectively labels K opioid receptors in guinea-pig whole 
brain. In these current studies, using protection from inactivation by fl-chloronaltrexamine (fl-CNA), we are able to 
demonstrate that although dynorphin A prefers x receptors, it will label bt receptors when t¢ receptors are not 
available, or present in only a small number. Thus, differences in numbers of ~ and t¢ receptors present in brain 
preparations are critical in determining the receptor binding profile of [3H]dynorphin A across species. Additionally, 
although all the prodynorphin derived peptides show r preference, the ability of the other prodynorphin derived 
peptides to compete with [3H]dynorphin A for its receptor varies across species. Consequently, in a highly enriched t¢ 
preparation such as monkey cerebral cortex, [3H]dynorphin A appears to label t¢ receptors with substantial selectivity, 
and the other prodynorphin-derived peptides show less ability to compete with dynorphin A for its receptor. In 
contrast, in a x-poor tissue such as rat brain, all of the prodynorphin-derived peptides, including dynorphin A-(l-8), 
show very similar potency. Thus, differences in i x and t¢ receptor numbers across brain regions and species lead to 
differences in the receptor binding profile of dynorphin A. 
Multiple opiate receptors Dynorphin 
I. Introduction 
The relationship between multiple forms of en- 
dogenous opioid peptides and various subtypes of 
opioid receptors is still being elucidated. The dis- 
covery of dynorphin (Goldstein et al., 1979), the 
elucidation of its precursor (Kakidani et al., 1982), 
and the realization that multiple active opioids are 
derived from it (Weber et al., 1982; Suda et al., 
1982; Kilpatrick et al., 1982; Fischli et al., 1982) 
have led to the at tempt to define the receptor 
profiles of the prodynorphin products (Chavkin et 
al., 1982; Corbett  et al., 1982; James et al., 1982). 
* To whom all correspondence should be addressed. 
Using guinea-pig ileum, James et al. (1984) 
have characterized the pharmacological selectivity 
of the prodynorphin products for the K receptor in 
that tissue. Although dynorphin A is the most 
potent of these peptides, dynorphin A, a-neo-en- 
dorphin and dynorphin B all are highly t~ selective. 
In contrast, dynorphin A-(l-8), a-neo-endorphin, 
and dynorphin B 29 appear to be less t~ selective. 
Corbett  et al. (1982), using guinea-pig whole brain, 
have shown that dynorphin A has the highest 
affinity at the x site, while dynorphin A-(l-9) and 
a-neo-endorphin show only slightly lower affinity 
than dynorphin A. In contrast, dynorphin A-(l-8) 
shows ten-fold less affinity for the x site than 
dynorphin A, although it still prefers x to/~ or 
sites. However, not all reports agree as to the 
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degree of selectivity for the r receptor exhibited by 
dynorphin A, dynorphin B, and a-neo-endorphin 
in brain preparations. While several reports dem- 
onstrate such a selectivity in the guinea-pig brain 
(Chavkin et al., 1982; Corbett et al., 1982; James 
et al., 1984), other reports suggest significant inter- 
actions of dynorphin with the/~ receptor (Quirion 
and Pert, 1981; Hewlett and Barchas, 1984). Since 
a number of these studies employed competition 
by the peptides against labeled '~' and 'x '  al- 
kaloids, it is possible that part of the confusion 
derived from the selectivity of the labeling ligands 
and the conditions of the assay. Therefore, we 
attempted to use [3H]dynorphin A to label and 
characterize brain opioid binding sites (Young et 
al., 1983a; Lewis et al., 1984). 
Based on our work in the guinea-pig brain 
homogenates, we concluded that [ 3 H]dynorphin A 
labels promarily x sites as suggested by others 
(Corbett et al., 1982; Wilster et al., 1980; 1981; 
Chavkin et al., 1982; James et al., 1984). However, 
in a preliminary report (Young et al., 1983b), we 
noted differences in the receptor selectivity of 
[3H]dynorphin A in guinea-pig and rat brain. 
While the binding of [3H]dynorphin A appeared 
to be extremely x selective in guinea-pig it was less 
so in rat brain. These differences paralleled those 
noted across various studies when other x ligands, 
e.g. MR 2034 (UM 1071) and ethylketocyclazocine 
(EKC), were used (Hiller and Simon, 1980; Pfeiffer 
and Herz, 1982; Gillan and Kosterlitz, 1982). This 
is probably due to a difference in the number of x 
sites in the two species with guinea-pig having 
approximately 2-3 times as many x sites as rat 
brain, while/t sites are more numerous in rat brain 
(Gillan and Kosterlitz, 1982). Thus, some of the 
confusion regarding x selectivity of putative x 
ligands may result from the use of rat vs. guinea-pig 
to characterize x binding. That is, a ligand that is 
x selective in guinea-pig brain shows less apparent 
x selectivity in K-poor tissues such as rat brain. In 
this paper, we address the issue directly. 
Using both [3H]dynorphin A and [3H]UM 1071 
(the active stereoisomer of MR 2034, a putative x 
ligand) we examined the relative ~ selectivity of 
the prodynorphin peptides in rat, guinea-pig and 
monkey brain. Since dynorphin A may label sites 
other than x sites, particularly in a K-poor tissue, 
we evaluated, the ability of the prodynorphin 
peptides to compete with [3H]dynorphin A for its 
sites. We were particularly interested in monkey 
brain since prototypical x ligand appear to be 
highly selective for x receptors in vivo in monkey 
(Hein et al., 1981). Using guinea-pig brain and rat 
brain homogenates as the prototypical x-rich and 
K-poor tissues respectively, we compared [3H]dy- 
norphin A binding in monkey cerebral cortex to 
that in guinea-pig and rat brain. To characterize 
the receptor profile of dynorphin A binding, we 
used both competition of various ligands against 
[3H]dynorphin A and [3H]UM 1071 binding, and 
selective protection from fl-CNA inactivation by/~ 
and x ligands. While we observe substantial x 
preference of the prodynorphin peptides in brain, 
we also report significant species differences in the 
receptor binding profile of [3H]dynorphin A as 
well as in the ability of prodynorphin peptides to 
compete with dynorphin A for its receptor. 
2. Materials and methods 
Receptor binding assays for [3H]UM 1071 were 
performed as described by Young et al. (1983c). 
[3 H]Bremazocine binding assays in the presence of 
100 nM [D-Ala 2,MePhe4,Gly-ol 5]enkephalin 
(DAGO) and 100 nM [D-Ser2,LeuS]enkephalin - 
Thr (DSLET) were performed at 4°C in a similar 
fashion. Rat and guinea-pig brain minus cerebel- 
lum were homogenized in 50 mM Tris buffer (pH 
7.4 at 25°C) with 5% DMSO added. Several rat or 
guinea-pig whole brains were pooled for homo- 
genization to assure differences between tissue pre- 
parations were attributable to between species 
rather than between animal variation. Rhesus 
monkey cortex was frozen on dry ice and stored at 
- 7 0 ° C  until ready for use. Random pieces of 
cortex, 1 g in weight, were used for each binding 
assay. Previous studies demonstrated no changes 
between fresh and frozen tissue in #, ~ or r 
receptor binding using [3H]morphine, [3H][D- 
Ala2,D-LeuS]enkephalin (DADL), [3H]UM 1071 
or [3 H]dynorphin A as labeling ligands (Young et 
al., 1983c). 
[3H]Dynorphin A binding was performed as 
described previously (Young et al., 1983a). In brief, 
[3H]dynorphin A binding was carried out in 50 
mM Tris buffer. Dynorphin A, a-neo-endorphin, 
dynorphin B and dynorphin A (1-8) were added in 
10/~1 volume in 1 : 1 mixture of methanol and 0.1 
N HCI. [3H]Dynorphin A was added in 100 /~1 
volume to yield a final concentration in the assay 
of 0.5-1 nM. Fifteen milligrams (wet weight) of 
crude membrane fragments were added to each 
tube in a total volume of 390/~1. After 90 min of 
incubation at 4°C, the bound [3H]dynorphin A 
was separated from the free by rapid filtration 
under vacuum over Whatman G F / B  glass fiber 
filters which had been presoaked in 50 mM Tris 
buffer containing 0.4% BSA (Fraction V, Sigma) 
and 0.1% polylysine (Sigma). Tris buffer with 0.1% 
BSA, 100 mM choline chloride and 0.01% Triton 
X-100 ([3H]fl-endorphin washing buffer (Law et 
al., 1979)) was used as the washing buffer. Using 
this procedure, [3H]dynorphin A binding to filters 
is reduced to approximately 5%. UM 1071 (a 
putative ~¢ ligand) or levorphanol, 1/~M, was used 
to define non-specific binding. Specific binding of 
[3H]dynorphin A to guinea-pig and monkey brain 
averaged 50%. Specific binding to rat brain, under 
the same conditions, averaged 40%. 
Protection from irreversible binding to the al- 
kylating agent fl-chloronaltrexamine (fl-CNA) by 
either morphine or dynorphin was performed as 
described by James et al. (1982) with the following 
modifications: protection and fl-CNA inactivation 
was performed in 50 mM Tris buffer rather than 
Krebs buffer, and these reactions are carried out 
with brain tissueS/at a concentration of 50 mg/ml.  
The concentration of dynorphin A used for protec- 
tion was 10 nM and 100 nM. The concentration 
used for morphine protection was 10 nM, since 
morphine shows the greatest /t selectivity in the 
range of 10 nM or less. 
After incubation at 37°C for 20 rain to dissoci- 
ate endogenous ligands, the membranes were 
centrifuged at 40 000 x g for 10 min, resuspended 
in 50 mM Tris buffer at a concentration of 50 mg 
t issue/ml buffer, then incubated 5 min at 37°C 
with the protecting ligand, f l -CNA was added at 
concentrations of 100 nM to 1 /xM for 15 min at 
37°C to inactivate other opiate receptors. After 15 
min, the membranes were diluted four-fold in Tris 
buffer than centrifuged at 25 000 × g for 5 min, 
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resuspended in 50 mM Tris buffer then centri- 
fuged again for a total of six washes. After these 
washes, the membranes were incubated at 37°C 
for 20 min, then washed two more times before 
resuspension in Tris buffer at the final concentra- 
tion of 37.5 mg tissue/ml buffer for the binding 
assay. All binding kinetics were done with iterative 
non-linear computer analysis (Ligand, Munson and 
Rodbard). Curves for ICs0s were drawn by hand, 
but represented a mean of at least three de- 
terminations. 
3. Results 
3.1. Dynorphin A interaction with ~ and x sites in 
rat and guinea-pig 
Binding data using [3H]UM 1071 as the label- 
ing ligand for K sites showed the same K t) for rat 
and guinea-pig (rat = 1.4 + 0.6; guinea-pig = 1.3 
+ 0.5). In contrast the Bma x was two-fold different 
between species (rat Bma x = 227 + 18 pM; guinea- 
pig Bm~ x = 423 + 52 pM). Using [3H]bremazocine 
in the presence of 100 nM DAGO and DSLET to 
define x binding we observe similar K D of 
bremazocine at the K site between rat and guinea- 
pig (rat = 0.15 + 0.2; guinea-pig = 0.28 + 0.10). 
The K~ for dynorphin A at the r site is not 
significantly different between these two species 
(rat K~ dynorphin A = 0.2 + 0.1; guinea-pig K~ 
dynorphin A = 0.34 + 0.13). Likewise using 
[3H]DAGO to define # sites, the K l of dynorphin 
A at the # site does not differ between rat and 
guinea-pig (rat = 1.3 + 0.1, guinea-pig = 1.4 + 0.2). 
Thus, apparent differences in [3H]dynorphin A 
binding between these species cannot be attributed 
to different affinities at the # and r site, but rather 
differences in the proportion of /~ and x sites 
labeled by [3H]dynorphin A between these species. 
3.2. [3H]Dynorphin A binding in rat and guinea-pig 
Previous experiments using [3H]dynorphin A in 
rat and guinea-pig brain suggested substantial dif- 
ferences between species in the ability of morphine 
to displace [3H]dynorphin A binding (Young et 
al., 1983b). In rat, the ICs0 of morphine in compe- 
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Fig. 1. The competition curves of dynorphin A and UM 1071 
against [3H]dynorphin A in the absence and presence of/~ and 
tition with [3H]dynorphin A is substantially lower 
than the IC50 of morphine versus [3 H]dynorphin A 
in guinea-pig brain, suggesting that [3H]dynorphin 
A labels both /z and x receptors in rat brain. To 
further characterize the/~ and K nature of [3H]dy- 
norphin A binding, experiments using suppression 
of /~ and 8 binding were undertaken in rat and 
guinea-pig brain. Addition of 100 nM morphine 
plus 100 nM DADL to [3H]dynorphin A binding 
in rat brain results in the loss of 90% of the 
binding, again suggesting that [3H]dynorphin A 
labels both /~ and x receptors in rat brain. In 
guinea-pig brain (fig. 1A) there is a slight shift in 
the ICs0 of dynorphin A against itself (1.2-2.4 nM) 
in the presence of morphine and DADL. In con- 
trast, the IC50 of UM 1071 against [3H]dynorphin 
A binding is unchanged by the addition of 100 nM 
morphine and D A D L  (IC50 = 1 nM in both cases) 
(fig. 1B). 
Further support for the labeling of a mixture of 
/~ and x sites in brain can be demonstrated by 
equilibrium binding kinetics. Such studies must be 
interpreted with caution, since breakdown occurs 
during the course of the incubation, and the ad- 
dition of unlabeled dynorphin can change the rate 
of breakdown of the labeled ligand. Consequently, 
effort was made to include only those concentra- 
tion ranges over which breakdown is constant for 
these computations. The apparent K D of dy- 
norphin A in rat brain is higher than the apparent 
K D in guinea-pig brain (rat = 2.9 + 0.7, guinea-pig 
= 1.3 + 0.25). The number of sites labeled in both 
species is similar (rat = 226 + 43, guinea-pig = 174 
_+ 22). This is not surprising, since dynorphin A is 
an endogenous ligand, and should have ample 
receptors in both species. The higher K D in rat 
brain would be expected if [3H]dynorphin A is 
also labeling ~ receptors, towards which dy- 
norphin A has a lower affinity than it has for x 
receptors. 
6 selective ligands at blocking concentrations in guinea-pig 
whole brain homogenates. Addition of 100 nM morphine and 
DADL resulted in only slight shift in the IC50 of dynorphin A 
(A) and no shift in the IC50 of UM 1071 (B). 
TABLE 1 





[ 3 H]Dihydromorphine 
(0.5 nM) 100 11 
[ 3 H]Dynorphin A 
(0.5 nM) 100 34 
fl-CNA treatment Washing controls 
10 nM Dyn 10 nM Mor 10 nM 10 nM 
+ + Dyn A Mor 
CNA CNA alone alone 
84 100 84 
66 98 84 
0 
89 
3.3. fl-CNA inactivation studies with [~H]dynorphin 
A 
Since [3H]dynorphin A appears to label both/~ 
and K receptors in rat brain, fl-CNA inactivation 
and protection experiments to demonstrate the x 
selectivity of [3H]dynorphin A binding were un- 
dertaken only in guinea-pig brain, a x-rich tissue. 
The protection from fl-CNA inactivation experi- 
ments (table 1) again shows that 10 nM dynorphin 
A can protect [3H]dynorophin A binding sites 
with approximately 90% recovery of the sites. The 
non-/~ nature of these sites is indicated by the 
failure of [3H]dihydromorphine to label these sites. 
Higher protecting concentrations (100 nM) of dy- 
norphin A resulted in a low recovery of [3H]dy- 
norphin A binding after washing. While morphine 
(10 nM) protects [3H]dihydromorphine sites from 
inactivation by fl-CNA morphine (tables 1 and 
2), these morphine or/~ sites can also be labeled by 
[3H]dynorphin A. The t~ nature of this [3H]dy- 
norphin A binding is demonstrated by a six-fold 
decrease in the IC50 of morphine against [3H]dy- 
norphin A (table 2). In contrast, there is no shift in 
the IC50 of morphine against [3H]dihydro- 
morphine. This suggests that although dynorphin 
A prefers x sites, it will label /~ sites when x sites 
are no longer available. This is consistent with the 
data on [3H]dynorphin A binding in rat brain, a 
x-poor tissue, which shows that [3H]dynorphin A 
labels a substantial number  of ~t as well as x 
receptors in rat brain. Of interest is the finding 
that [3H]dynorphin A binding sites appear to be 
more resistant to inactivation by f l-CNA than 
[3H]dihydromorphine sites, so that concentrations 
of 100 nM to 1 /~M fl-CNA, which appear to 
inactivate 90% of dihydromorphine sites, show 
between 50-70% inactivation of [3H]dynorphin A 
sites. 
3. 4. Studies in the rhesus monkey 
Since [3H]dynorphin A appears to label pri- 
marily x sites in guinea-pig brain, but both/~ and 
x sites in rat brain, the question of tissue-depen- 
dent ligand selectivity was pursued in another 
species, rhesus monkey, in which x receptors have 
been explored at a behavioral level (Hein et al., 
1981). Again, substantial species differences in 
[3H]dynorphin A binding to/~ and ~ receptors are 
seen (figs. 2A, 3C, 4E and table 3). Similar species 
differences were observed in competition studies 
using [3H]UM 1071 as a putative K ligand (figs. 
2B, 3D, 4F). These studies indicate that, with 
respect to x selectivity, it appears that monkey 
cerebral cortex more closely resembles guinea-pig 
TABLE 2 
Selectivity of morphine protected [3H]dynorphin A binding 
sites after fl-CNA inactivation. 
Conditions Control fl-CNA + fl-CNA 
10 nM Mor alone 
[ 3H]Dihydromorphine 
Remaining binding (%) 100 84 
Morphine IC50 (nM) 2 2 
[~H]Dynorphin A binding 
Remaining binding 100 66 34 
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Fig. 2. The competition curves of dynorphin A, UM 1071, morphine and DADL against [3H]dynorphin A and [3H]UM 1071, a K 
selective opiate alkaloid in guinea-pig brain. Both [3H]dynoprhin A and [3H]UM 1071 label a site towards which morphine and 
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C 100 ~ - ~ t X . . . : H  Dynorphin/Rat Brain 
. o - \ \  "... .o\ \ . :  
,o ~ \ , oA,x. 
60 \ .~NI -17 \  \ .  ~, 
"-~ ~ ~\~ 
o 40 




9 0  
8 0  
7O 









.~ 3H UM 1071/Rat Brain 




" \ .  \ 1o 
J I ~ ~ x l  I I I I , 
1 5 2 125 1000 1 5 25 125 1000 
[Comg¢,ting Ligand] nM ~ompeting Ligand] nM 
Fig. 3. The competition curves of dynorphin A, UM 1071, morphine and DADL against [3H]dynorphin A and [3H]UM 1071 in rat 
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than guinea-pig brain. 
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monkey cortex. In monkey cerebral cortex both [3H]dynoprhin A and [3H]UM 1071 appear to label a similar site that is very non- F 
and non-8, suggesting a profile similar to guinea-pig whole brain. 
TABLE 3 
IC5o of various opiate ligands vs. [3H]dynorphin A (nM). 
Rat Guinea-pig Monkey 
Morphine 32 680 > 1000 
DADL 300 > 1000 > 1000 
Dynorphin A 2.4 1.2 0.8 
UM 1071 2.0 1.1 0.7 
than rat brain. Both [3H]dynorphin A and [3H]UM 
1071 appear to label r sites more exclusively in 
monkey cortex than guinea-pig whole brain (fig. 
3). Both dynorphin A and UM 1071, show a 
500-1000-fold lower IC50 than morphine or DADL 
against [3H]dynorphin A or [3H]UM 1071 binding 
in guinea-pig or monkey brain (figs. 2, 3, 4 and 
table 3). 
3.5. Displacement profile of pro-dynorphin products 
Comparing the prodynorphin peptides among 
three species, the similarity of dynorphin A, dy- 
norphin B and a-neo-endorphin in displacing 
[3H]dynorphin A is quite evident (table 4). How- 
ever, dynorphin A-(1-8) has more difficulty in 
competing with [3H]dynorphin A in all species. 
This is demonstrated in guinea-pig brain, where 
TABLE 4 
IC5o of prodynorphin peptides vs. [3H]dynoprhin A (1 nM). 
DYN A DYN B DYN A-(l-8) a-Nco-End IC5o DYN A-(1-8) 
ICso DYN A 
Rat 4.5 nM +0.6 4.0 nM 5:1.3 11 nM5:5 1.6 nM +0.1 
Guinea-pig 1.2 nM+0.3  1.8 nMs:0.5 14 nM+0.7  2.0 n M + l  





the ratio of IC50 dynorphin A-(1-8) to the ICs0 of 
dynorphin A is 12, in contrast to rat brain where 
the ratio is 2.4. Using [3H]UM 1071 as a labeling K 
ligand, a very similar pattern is seen, where dy- 
norphin A, dynorphin B and a-neo-endorphin ap- 
pear equivalent but dynorphin A(1-8) shows a 
four-fold higher ICs0 than dynorphin A. Previous 
work by Corbett et al. (1982) in guinea-pig brain 
has shown that dynorphin A-(1-8), while demon- 
strating r affinity retains/~ and 6 receptor proper- 
ties. Thus, the processing of dynorphin A to dy- 
norphin A-(l-8) differentially affects its x selectiv- 
ity among species. 
4. Discussion 
The present studies provide evidence that pro- 
dynorphin-derived peptides can exhibit marked 
selectivity for ~¢ binding sites. Our data are con- 
sistent with previous experiments by James et al. 
(1984) with guinea-pig ileum showing that dy- 
norphin A, dynorphin B and a-neo-endorphin 
show similar pharmacological K selectivity, while 
dynorphin A-(1-8) shows less x selectivity than 
these other prodynorphin peptides. Similarly, 
Corbett et al. (1982) using [3H]bremazocine in the 
presence of unlabeled/~ and 8 ligands, have shown 
dynorphin A, dynorphin A-(1-8), dynorphin A-(l- 
9), and a-neo-endorphin are selective for K recep- 
tors in guinea-pig brain. However, our results indi- 
cate dynorphin A sites are not necessarily identical 
to the K site. Thus, dynorphin A binding may 
represent a preponderance of x binding along with 
a proportion of/ t  binding depending on the species 
and possibly brain region under study. For exam- 
ple, in the fl-CNA selective protection studies with 
guinea-pig brain, sites protected with dynorphin A 
later showed binding of [3H]dynorphin A, but not 
[3H]dihydromorphine, a finding consistent with 
the ~ selectivity hypothesis. However, in con- 
tradiction to this hypothesis,/~ sites protected with 
morphine also showed binding of [3H]dynorphin 
A, with increased sensitivity to displacement by 
morphine. As discussed below, the x selectivity 
issue was also addressed in experiments which 
exploited species differences in the relative abun- 
dance of opioid receptor subtypes. 
When comparing across the three species and 
tissue preparations, rat brain, guinea-pig brain and 
monkey cortex, the K selectivity of dynorphin A 
becomes increasingly evident. In rat, dynorphin 
shows a low x selectivity in contrast to guinea-pig 
whole brain or monkey cortex. This increasing x 
selectivity is reflected in the progressive decrease 
in the IC50 of dynorphin A against itself, and the 
progressive increase in the IC50 of morphine and 
DADL against [3H]dynorphin A. This same 
cross-species pattern is obtained using [3H]UM 
1071, a • opiate alkaloid, indicating that monkey 
cerebral cortex is highly enriched in K opioid 
receptors. This agrees with other work showing K 
receptors present in the deep cortex of guinea-pig 
(Goodman and Snyder, 1982), as well as our own 
work showing that [3H]dynorphin A labels these 
same deep cortical layers in guinea-pig brain as 
does [3 H]bremazocine in the presence of unlabeled 
/~ and 8 ligands (Lewis et al., 1984; Lewis et al., 
unpublished observations). This also supports 
much of the in vivo behavioral data with ~ com- 
pounds in primates (Hein et al., 1982). 
By using [ 3H]dynorphin A as the labeling ligand, 
we are able to compare directly the ability of these 
prodynorphin peptides to compete for the dy- 
norphin A binding site across the species. Thus, in 
guinea-pig, dynorphin A, dynorphin B and c~-neo- 
endorphin appear to compete well for this same 
'dynorphin A' site, while dynorphin A-(l-8) shows 
less ability to compete with dynorphin A, its 
parent/precursor peptide. In contrast, in rat brain, 
the ratio of the IC50 of dynorphin A to the IC50 of 
dynorphin A(1-8) is much lower, suggesting that 
the processing of dynorphin A to dynorphin A-(l- 
8) has less impact on its ability to compete with 
dynorphin A for the same receptor. This species 
difference in the ability of dynorphin A-(l-8) to 
compete for dynorphin A receptors may be depen- 
dent upon the difference in numbers /~ and x 
receptors in these systems. Thus, in situations 
where dynorphin A labels # as well as K receptors, 
dynorphin A-(1-8) is able to compete well for 
dynorphin A binding sites. This suggests that, in 
rat, the processing of dynorphin A to dynorphin 
A-(1-8) results in less change in receptor selectivity 
of the product dynorphin A-(l-8) than pharmaco- 
logical studies in guinea-pig may suggest. This is 
not the case for guinea-pig or monkey brain where 
dynorphin A-(1-8) is much less able to compete 
with dynorphin A than in rat. It is of interest that 
work by Weber et al. (1982), Dores et al. (1985) 
and Lewis et al. (1985) have shown a predomi- 
nance of dynorphin A-(l-8) in most brain regions 
of rat, while in guinea-pig there is substantially 
less processing of dynorphin A to dynorphin A(1- 
8). 
Recent work by Quirion and Pilapil (1984) with 
[3Hldynorphin A(1-8) in rat and guinea-pig brain 
suggest r selectivity of this ligand. Binding and 
competition studies were conducted in the pres- 
ence of 100 mM NaCI, which greatly reduces the 
ability of morphine to bind and compete with this 
ligand. Nonetheless, their data shows a five-fold 
lower ICso of morphine in rat brain than guinea-pig 
brain, suggesting this ligand may label some ~t 
receptors in rat brain. Likewise, Gillan et al. (1985) 
have also shown x selectivity for [3H]dynorphin 
A-(1-8). This supports earlier work that dynorphin 
A-(1-8) prefers r although it is not as selective as 
dynorphin A, its parent compound (Corbett et al., 
1982). 
In monkey cerebral cortex, differences between 
the various prodynorphin peptides begin to emerge. 
Thus, dynorphin B and a-neo-endorphin appear 
to be less able to compete for the same receptors 
as dynorphin A in this tissue, since the ICs0 of 
these peptides against [3H]dynorphin A is ap- 
proximately three-fold higher than the ICs0 of 
dynorphin A against itself. While we did not see 
differences between dynorphin A and a-neo-en- 
dorphin in guinea-pig brain, the work in monkey 
cortex is in agreement with the work of Corbett et 
al. (1982) in guinea-pig brain showing that the K~ 
of a-neo-endorphin is two-fold higher than dy- 
norphin A for the r site. Thus, in a r-enriched 
tissue such as cerebral cortex, dynorphin A more 
exclusively labels r sites, and the ICs0 of dy- 
norphin A against itself decreases. 
We cannot eliminate the possibility that, across 
species, differential breakdown of these prody- 
norphin peptides is responsible for the changes in 
their ability to compete with dynorphin A for its 
receptor. Indeed, in preliminary studies in guinea- 
pig brain, we have found that the presence of 1 
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#M a-neo-endorphin does not affect the amino 
peptidase action against [3 H]dynorphin A, while 1 
#M dynorphin A substantially inhibits the break- 
down of [-~H]dynoprhin A. This might suggest that 
different enzymes are responsible for the N termi- 
nal cleavage of tyrosine from these various opioid 
peptides. Such differences in breakdown of various 
prodynorphin peptides in vitro may be physiologi- 
cally relevant, since, in vivo, these peptides are 
likely to be released simultaneously from the same 
terminals and would be competing for the same 
receptors. Consequently, differences in the number 
of opioid receptor types as well as differences in 
the receptor selectivity, processing to smaller forms, 
and breakdown of these prodynorphin peptides 
after release may all be cellular strategies for en- 
coding biological information in the different pro- 
dynorphin peptides. The demonstration of a num- 
ber on nonopioid effects produced by dynorphin 
A and dynorphin A-(2-17) (Walker et al., 1982a,b; 
Przewlocki et al., 1983) further supports the con- 
cept of multiple cores of information, both opioid 
and nonopioid, contained in the same pro- 
hormone. These differences in binding paradigms 
seen across species may product distinct behav- 
ioral and pharmacological profiles of these peptides 
in these different species. 
In conclusion, [3H]dynorphin A appears to 
selectively label x receptors in x receptor-rich 
tissues (guinea-pig brain and monkey cerebral 
cortex). Dynorphin B and a-neo-endorphin appear 
to compete well with dynorphin A for these sites 
in guinea-pig brain but somewhat less well in 
monkey cerebral cortex. The processing of dy- 
norphin A to dynorphin A-(l-8) affects its ability 
to compete with dynorphin A for the same recep- 
tors in guinea-pig brain and monkey cerebral 
cortex. In contrast, this processing of dynorphin A 
to dynorphin A-(l-8) has less effect in rat brain, 
where dynoprhin A labels a less pure receptor 
population. There may be differences in the opioid 
inactivation of these prodynorphin peptides that 
further modify the actions of these peptides on 
receptors after their simultaneous release from 
nerve terminals. Such differences across species 
may result in different behavioral and pharmaco- 
logical profiles for these prodynorphin peptides. 
Even though dynorphin A is a highly selective 
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ligand and has a lower affinity to the/~ sites, its 
high potency imparts to it a substantial ability to 
interact at the # site. It appears that the other 
prodynorphin K selective products (dynorphin B, 
a-neo-endorphin) possess similar characteristics. 
Thus, whether prodynorphin products act at # or 
K sites will in part depend on the relative abun- 
dance of receptors available in the vicinity of the 
prodynorphin terminals, which will vary as a func- 
tion of brain region and species. 
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